Neumora Therapeutics (NMRA) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order virtually by the Chairman and CEO, with all board members and executive officers present.

• The agenda and rules of conduct were made available to attendees, and the meeting was held in accordance with the company's bylaws.

Board and executive committee updates

• The board included Kristina Burow, Matthew Fust, Alaa Halawa, Maykin Ho, and David Piacquad, with Paul Berns as Chairman and CEO.

Overview of voting outcomes

• All Class III director nominees were re-elected for three-year terms.

• Ernst & Young LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.

• Executive officer compensation was approved on an advisory basis.

• Annual frequency for future advisory votes on executive compensation was approved.

• Final voting results will be filed in a Form 8-K with the SEC within four business days.